Cotroneo Pat 4

4 · FIBROGEN INC · Filed Sep 4, 2020

Form 4

Period: 2020-09-03

VP, Finance and CFO

Transactions

Exercise/Conversion
Common Stock
2020-09-03$29.66/sh+637$18,893→ 278,947 total
Exercise/Conversion
Common Stock
2020-09-03$25.40/sh+8,671$220,243→ 293,314 total
Sale
Common Stock
2020-09-03$50.91/sh−15,004$763,854→ 278,310 total
Exercise/Conversion
Stock Option (Right to Buy)
2020-09-03−637→ 4,618 total
Exercise: $29.66Exp: 2025-03-04→ Common Stock (637 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2020-09-03−8,671→ 41,579 total
Exercise: $25.40Exp: 2027-03-08→ Common Stock (8,671 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2020-09-03−5,696→ 0 total
Exercise: $19.39Exp: 2026-02-22→ Common Stock (5,696 underlying)
Exercise/Conversion
Common Stock
2020-09-03$19.39/sh+5,696$110,445→ 284,643 total

Footnotes (4)

[F1]Shares sold pursuant to a 10b5-1 plan.
[F2]The shares were sold at prices ranging from $50.89 to $51.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F3]Fully vested.
[F4]Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in equal amounts quarterly thereafter for the following three years.

Documents

1 file